Abstract

Ca(2+)/calmodulin (CaM)-dependent protein kinase II (CaMKII) is a major mediator of physiological glutamate signaling involved in higher brain functions. Here, we show CaMKII involvement in pathological glutamate signaling relevant in stroke. The novel inhibitor tatCN21 was neuroprotective even when added hours after glutamate insults. By contrast, the "traditional" inhibitor KN93 attenuated excitotoxicity only when present during the insult. Both inhibitors efficiently blocked Ca(2+)/CaM-stimulated CaMKII activity, CaMKII interaction with NR2B and aggregation of CaMKII holoenzymes. However, only tatCN21 but not KN93 blocked the Ca(2+)-independent "autonomous" activity generated by Thr-286 autophosphorylation, the hallmark feature of CaMKII regulation. Mutational analysis further validated autonomous CaMKII activity as the drug target crucial for post-insult neuroprotection. Overexpression of CaMKII wild type but not the autonomy-deficient T286A mutant significantly increased glutamate-induced neuronal death. Maybe most importantly, tatCN21 also significantly reduced infarct size in a mouse stroke model (middle cerebral arterial occlusion) when injected (1 mg/kg intravenously) 1 h after onset of arterial occlusion. Together, these data demonstrate that inhibition of autonomous CaMKII activity provides a promising therapeutic avenue for post-insult neuro-protection after stroke.

Highlights

  • Glutamate is the most abundant excitatory neurotransmitter in the mammalian brain

  • CaMKII inhibitors derived from the autoinhibitory region, such as AC3-I and AIP, inhibit other protein kinases such as myosin light chain kinase (MLCK), PKA, and PKD (38 – 40), and some studies indicated a low potency of CaMKII inhibition (IC50 ϳ30 ␮M) [41]

  • CaMKII is well established as an important mediator of physiological glutamate signals (14 –17), but its role in pathological excitotoxic glutamate signaling has been less clear

Read more

Summary

Neuroprotection by Inhibiting CaMKII Autonomy

We demonstrated a role for CaMKII in glutamate excitotoxicity by several lines of evidence. The CaMKII inhibitor tatCN21 was neuroprotective when applied hours after a glutamate insult in vitro or in a mouse stroke model. Biochemical and mutational analysis identified the “autonomous” form of CaMKII activity as the relevant drug target for post-insult neuroprotection

EXPERIMENTAL PROCEDURES
RESULTS
Further Pharmacological Evidence That CaMKII but Not
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call